Equillium & Biocon Expand Exclusive Licensing Agreement for Itolizumab to Include Australia and New Zealand

LA JOLLA, Calif. and BENGALURU, India, Dec. 12, 2019 (GLOBE NEWSWIRE) — Equillium Inc. (Nasdaq: EQ), a clinical-stage biotechnology company leveraging deep understanding of immunobiology to develop products to treat severe autoimmune and inflammatory disorders, and Biocon Ltd (BSE code: 532523, NSE: BIOCON), an innovation-led global biopharmaceuticals company, today announced that they have expanded their collaboration and license agreement for itolizumab to grant Equillium exclusive rights for developing and commercializing itolizumab in Australia and New Zealand.

Click to view original post